nodes	percent_of_prediction	percent_of_DWPC	metapath
Zoledronate—ABCC1—Dactinomycin—muscle cancer	0.261	0.34	CbGbCtD
Zoledronate—ABCC1—Vincristine—muscle cancer	0.16	0.21	CbGbCtD
Zoledronate—ABCC1—Etoposide—muscle cancer	0.147	0.192	CbGbCtD
Zoledronate—ABCC1—Doxorubicin—muscle cancer	0.1	0.131	CbGbCtD
Zoledronate—ABCC1—Methotrexate—muscle cancer	0.0971	0.127	CbGbCtD
Zoledronate—GGPS1—renal system—muscle cancer	0.00549	0.0773	CbGeAlD
Zoledronate—GGPS1—cardiac atrium—muscle cancer	0.00492	0.0692	CbGeAlD
Zoledronate—GGPS1—tendon—muscle cancer	0.00429	0.0603	CbGeAlD
Zoledronate—GGPS1—bone marrow—muscle cancer	0.00415	0.0584	CbGeAlD
Zoledronate—GGPS1—vagina—muscle cancer	0.00398	0.056	CbGeAlD
Zoledronate—GGPS1—head—muscle cancer	0.00367	0.0517	CbGeAlD
Zoledronate—GGPS1—testis—muscle cancer	0.00355	0.0499	CbGeAlD
Zoledronate—CA14—cardiac atrium—muscle cancer	0.00294	0.0414	CbGeAlD
Zoledronate—Risedronate—PTGS2—muscle cancer	0.00269	0.529	CrCbGaD
Zoledronate—FDPS—smooth muscle tissue—muscle cancer	0.00263	0.037	CbGeAlD
Zoledronate—CA14—tendon—muscle cancer	0.00256	0.036	CbGeAlD
Zoledronate—CA12—renal system—muscle cancer	0.00256	0.036	CbGeAlD
Zoledronate—FDPS—renal system—muscle cancer	0.00253	0.0356	CbGeAlD
Zoledronate—Clodronate—PTGS2—muscle cancer	0.0024	0.471	CrCbGaD
Zoledronate—FDPS—cardiac atrium—muscle cancer	0.00227	0.0319	CbGeAlD
Zoledronate—FDPS—tendon—muscle cancer	0.00198	0.0278	CbGeAlD
Zoledronate—FDPS—bone marrow—muscle cancer	0.00191	0.0269	CbGeAlD
Zoledronate—FDPS—vagina—muscle cancer	0.00183	0.0258	CbGeAlD
Zoledronate—CA2—embryo—muscle cancer	0.00174	0.0244	CbGeAlD
Zoledronate—CA12—head—muscle cancer	0.00171	0.0241	CbGeAlD
Zoledronate—FDPS—head—muscle cancer	0.00169	0.0238	CbGeAlD
Zoledronate—FDPS—testis—muscle cancer	0.00164	0.023	CbGeAlD
Zoledronate—CA2—smooth muscle tissue—muscle cancer	0.00137	0.0192	CbGeAlD
Zoledronate—ABCC1—cardiac atrium—muscle cancer	0.00132	0.0185	CbGeAlD
Zoledronate—CA2—renal system—muscle cancer	0.00131	0.0185	CbGeAlD
Zoledronate—CA2—cardiac atrium—muscle cancer	0.00118	0.0166	CbGeAlD
Zoledronate—ABCC1—tendon—muscle cancer	0.00115	0.0161	CbGeAlD
Zoledronate—ABCC1—vagina—muscle cancer	0.00106	0.015	CbGeAlD
Zoledronate—CA2—tendon—muscle cancer	0.00103	0.0144	CbGeAlD
Zoledronate—CA2—bone marrow—muscle cancer	0.000994	0.014	CbGeAlD
Zoledronate—CA2—vagina—muscle cancer	0.000952	0.0134	CbGeAlD
Zoledronate—ABCC1—testis—muscle cancer	0.00095	0.0134	CbGeAlD
Zoledronate—CA2—head—muscle cancer	0.000879	0.0124	CbGeAlD
Zoledronate—CA2—testis—muscle cancer	0.00085	0.012	CbGeAlD
Zoledronate—Renal impairment—Doxorubicin—muscle cancer	0.000353	0.00223	CcSEcCtD
Zoledronate—Paraesthesia—Vincristine—muscle cancer	0.000353	0.00223	CcSEcCtD
Zoledronate—Malaise—Etoposide—muscle cancer	0.000352	0.00222	CcSEcCtD
Zoledronate—Vertigo—Etoposide—muscle cancer	0.00035	0.00221	CcSEcCtD
Zoledronate—Leukopenia—Etoposide—muscle cancer	0.000349	0.0022	CcSEcCtD
Zoledronate—Abdominal pain—Dactinomycin—muscle cancer	0.000348	0.00219	CcSEcCtD
Zoledronate—Body temperature increased—Dactinomycin—muscle cancer	0.000348	0.00219	CcSEcCtD
Zoledronate—Loss of consciousness—Etoposide—muscle cancer	0.000343	0.00216	CcSEcCtD
Zoledronate—Lethargy—Doxorubicin—muscle cancer	0.000343	0.00216	CcSEcCtD
Zoledronate—Decreased appetite—Vincristine—muscle cancer	0.000341	0.00216	CcSEcCtD
Zoledronate—Cough—Etoposide—muscle cancer	0.00034	0.00215	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Vincristine—muscle cancer	0.000339	0.00214	CcSEcCtD
Zoledronate—Fatigue—Vincristine—muscle cancer	0.000339	0.00214	CcSEcCtD
Zoledronate—Convulsion—Etoposide—muscle cancer	0.000338	0.00213	CcSEcCtD
Zoledronate—Hypertension—Etoposide—muscle cancer	0.000337	0.00213	CcSEcCtD
Zoledronate—Pain—Vincristine—muscle cancer	0.000336	0.00212	CcSEcCtD
Zoledronate—Constipation—Vincristine—muscle cancer	0.000336	0.00212	CcSEcCtD
Zoledronate—Osteoarthritis—Doxorubicin—muscle cancer	0.000336	0.00212	CcSEcCtD
Zoledronate—Pain in extremity—Doxorubicin—muscle cancer	0.000336	0.00212	CcSEcCtD
Zoledronate—Asthma—Methotrexate—muscle cancer	0.000335	0.00212	CcSEcCtD
Zoledronate—Chest pain—Etoposide—muscle cancer	0.000332	0.0021	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00033	0.00208	CcSEcCtD
Zoledronate—Discomfort—Etoposide—muscle cancer	0.000328	0.00207	CcSEcCtD
Zoledronate—Hypersensitivity—Dactinomycin—muscle cancer	0.000324	0.00205	CcSEcCtD
Zoledronate—Abdominal discomfort—Methotrexate—muscle cancer	0.000321	0.00203	CcSEcCtD
Zoledronate—Gastrointestinal pain—Vincristine—muscle cancer	0.000321	0.00203	CcSEcCtD
Zoledronate—Confusional state—Etoposide—muscle cancer	0.000321	0.00203	CcSEcCtD
Zoledronate—Pancytopenia—Methotrexate—muscle cancer	0.000318	0.00201	CcSEcCtD
Zoledronate—Anaphylactic shock—Etoposide—muscle cancer	0.000318	0.00201	CcSEcCtD
Zoledronate—Infection—Etoposide—muscle cancer	0.000316	0.002	CcSEcCtD
Zoledronate—Asthenia—Dactinomycin—muscle cancer	0.000315	0.00199	CcSEcCtD
Zoledronate—Blood creatinine increased—Doxorubicin—muscle cancer	0.000315	0.00199	CcSEcCtD
Zoledronate—Neutropenia—Methotrexate—muscle cancer	0.000313	0.00198	CcSEcCtD
Zoledronate—Dehydration—Doxorubicin—muscle cancer	0.000312	0.00197	CcSEcCtD
Zoledronate—Thrombocytopenia—Etoposide—muscle cancer	0.000312	0.00197	CcSEcCtD
Zoledronate—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000311	0.00197	CcSEcCtD
Zoledronate—Tachycardia—Etoposide—muscle cancer	0.000311	0.00196	CcSEcCtD
Zoledronate—Abdominal pain—Vincristine—muscle cancer	0.000311	0.00196	CcSEcCtD
Zoledronate—Body temperature increased—Vincristine—muscle cancer	0.000311	0.00196	CcSEcCtD
Zoledronate—Skin disorder—Etoposide—muscle cancer	0.000309	0.00195	CcSEcCtD
Zoledronate—Hyperhidrosis—Etoposide—muscle cancer	0.000308	0.00194	CcSEcCtD
Zoledronate—Abdominal pain upper—Doxorubicin—muscle cancer	0.000307	0.00194	CcSEcCtD
Zoledronate—Hypokalaemia—Doxorubicin—muscle cancer	0.000306	0.00193	CcSEcCtD
Zoledronate—Anorexia—Etoposide—muscle cancer	0.000303	0.00192	CcSEcCtD
Zoledronate—Diarrhoea—Dactinomycin—muscle cancer	0.000301	0.0019	CcSEcCtD
Zoledronate—Nasopharyngitis—Doxorubicin—muscle cancer	0.0003	0.0019	CcSEcCtD
Zoledronate—Infestation NOS—Methotrexate—muscle cancer	0.000299	0.00189	CcSEcCtD
Zoledronate—Infestation—Methotrexate—muscle cancer	0.000299	0.00189	CcSEcCtD
Zoledronate—Depression—Methotrexate—muscle cancer	0.000298	0.00188	CcSEcCtD
Zoledronate—Hypotension—Etoposide—muscle cancer	0.000297	0.00188	CcSEcCtD
Zoledronate—Gastritis—Doxorubicin—muscle cancer	0.000297	0.00188	CcSEcCtD
Zoledronate—Muscular weakness—Doxorubicin—muscle cancer	0.000296	0.00187	CcSEcCtD
Zoledronate—Renal failure—Methotrexate—muscle cancer	0.000294	0.00186	CcSEcCtD
Zoledronate—Abdominal distension—Doxorubicin—muscle cancer	0.000292	0.00184	CcSEcCtD
Zoledronate—Stomatitis—Methotrexate—muscle cancer	0.000291	0.00184	CcSEcCtD
Zoledronate—Conjunctivitis—Methotrexate—muscle cancer	0.00029	0.00183	CcSEcCtD
Zoledronate—Influenza—Doxorubicin—muscle cancer	0.00029	0.00183	CcSEcCtD
Zoledronate—Asthma—Doxorubicin—muscle cancer	0.00029	0.00183	CcSEcCtD
Zoledronate—Dysphagia—Doxorubicin—muscle cancer	0.00029	0.00183	CcSEcCtD
Zoledronate—Hypersensitivity—Vincristine—muscle cancer	0.000289	0.00183	CcSEcCtD
Zoledronate—Paraesthesia—Etoposide—muscle cancer	0.000286	0.0018	CcSEcCtD
Zoledronate—Haematuria—Methotrexate—muscle cancer	0.000285	0.0018	CcSEcCtD
Zoledronate—Dyspnoea—Etoposide—muscle cancer	0.000284	0.00179	CcSEcCtD
Zoledronate—Somnolence—Etoposide—muscle cancer	0.000283	0.00179	CcSEcCtD
Zoledronate—Asthenia—Vincristine—muscle cancer	0.000282	0.00178	CcSEcCtD
Zoledronate—Vomiting—Dactinomycin—muscle cancer	0.00028	0.00177	CcSEcCtD
Zoledronate—Agranulocytosis—Methotrexate—muscle cancer	0.000279	0.00176	CcSEcCtD
Zoledronate—Rash—Dactinomycin—muscle cancer	0.000277	0.00175	CcSEcCtD
Zoledronate—Decreased appetite—Etoposide—muscle cancer	0.000277	0.00175	CcSEcCtD
Zoledronate—Pancytopenia—Doxorubicin—muscle cancer	0.000276	0.00174	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Etoposide—muscle cancer	0.000275	0.00173	CcSEcCtD
Zoledronate—Fatigue—Etoposide—muscle cancer	0.000274	0.00173	CcSEcCtD
Zoledronate—Pain—Etoposide—muscle cancer	0.000272	0.00172	CcSEcCtD
Zoledronate—Constipation—Etoposide—muscle cancer	0.000272	0.00172	CcSEcCtD
Zoledronate—Neutropenia—Doxorubicin—muscle cancer	0.000271	0.00171	CcSEcCtD
Zoledronate—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.00027	0.0017	CcSEcCtD
Zoledronate—Diarrhoea—Vincristine—muscle cancer	0.000269	0.0017	CcSEcCtD
Zoledronate—Pollakiuria—Doxorubicin—muscle cancer	0.000268	0.00169	CcSEcCtD
Zoledronate—Urinary tract disorder—Methotrexate—muscle cancer	0.000265	0.00167	CcSEcCtD
Zoledronate—Weight increased—Doxorubicin—muscle cancer	0.000264	0.00167	CcSEcCtD
Zoledronate—Urethral disorder—Methotrexate—muscle cancer	0.000263	0.00166	CcSEcCtD
Zoledronate—Weight decreased—Doxorubicin—muscle cancer	0.000263	0.00166	CcSEcCtD
Zoledronate—Feeling abnormal—Etoposide—muscle cancer	0.000262	0.00166	CcSEcCtD
Zoledronate—Nausea—Dactinomycin—muscle cancer	0.000261	0.00165	CcSEcCtD
Zoledronate—Gastrointestinal pain—Etoposide—muscle cancer	0.00026	0.00164	CcSEcCtD
Zoledronate—Dizziness—Vincristine—muscle cancer	0.00026	0.00164	CcSEcCtD
Zoledronate—Infestation NOS—Doxorubicin—muscle cancer	0.000259	0.00163	CcSEcCtD
Zoledronate—Infestation—Doxorubicin—muscle cancer	0.000259	0.00163	CcSEcCtD
Zoledronate—Renal failure—Doxorubicin—muscle cancer	0.000254	0.00161	CcSEcCtD
Zoledronate—Urticaria—Etoposide—muscle cancer	0.000253	0.0016	CcSEcCtD
Zoledronate—Stomatitis—Doxorubicin—muscle cancer	0.000252	0.00159	CcSEcCtD
Zoledronate—Abdominal pain—Etoposide—muscle cancer	0.000252	0.00159	CcSEcCtD
Zoledronate—Body temperature increased—Etoposide—muscle cancer	0.000252	0.00159	CcSEcCtD
Zoledronate—Urinary tract infection—Doxorubicin—muscle cancer	0.000252	0.00159	CcSEcCtD
Zoledronate—Conjunctivitis—Doxorubicin—muscle cancer	0.000252	0.00159	CcSEcCtD
Zoledronate—Eye disorder—Methotrexate—muscle cancer	0.000251	0.00158	CcSEcCtD
Zoledronate—Vomiting—Vincristine—muscle cancer	0.00025	0.00158	CcSEcCtD
Zoledronate—Cardiac disorder—Methotrexate—muscle cancer	0.000249	0.00157	CcSEcCtD
Zoledronate—Rash—Vincristine—muscle cancer	0.000248	0.00156	CcSEcCtD
Zoledronate—Dermatitis—Vincristine—muscle cancer	0.000247	0.00156	CcSEcCtD
Zoledronate—Haematuria—Doxorubicin—muscle cancer	0.000247	0.00156	CcSEcCtD
Zoledronate—Headache—Vincristine—muscle cancer	0.000246	0.00155	CcSEcCtD
Zoledronate—Angiopathy—Methotrexate—muscle cancer	0.000243	0.00154	CcSEcCtD
Zoledronate—Immune system disorder—Methotrexate—muscle cancer	0.000242	0.00153	CcSEcCtD
Zoledronate—Mediastinal disorder—Methotrexate—muscle cancer	0.000242	0.00153	CcSEcCtD
Zoledronate—Agranulocytosis—Doxorubicin—muscle cancer	0.000241	0.00152	CcSEcCtD
Zoledronate—Chills—Methotrexate—muscle cancer	0.000241	0.00152	CcSEcCtD
Zoledronate—Alopecia—Methotrexate—muscle cancer	0.000237	0.0015	CcSEcCtD
Zoledronate—Bradycardia—Doxorubicin—muscle cancer	0.000236	0.00149	CcSEcCtD
Zoledronate—Mental disorder—Methotrexate—muscle cancer	0.000235	0.00148	CcSEcCtD
Zoledronate—Hypersensitivity—Etoposide—muscle cancer	0.000234	0.00148	CcSEcCtD
Zoledronate—Malnutrition—Methotrexate—muscle cancer	0.000234	0.00147	CcSEcCtD
Zoledronate—Erythema—Methotrexate—muscle cancer	0.000234	0.00147	CcSEcCtD
Zoledronate—Nausea—Vincristine—muscle cancer	0.000233	0.00147	CcSEcCtD
Zoledronate—Hypoaesthesia—Doxorubicin—muscle cancer	0.000231	0.00146	CcSEcCtD
Zoledronate—Urinary tract disorder—Doxorubicin—muscle cancer	0.000229	0.00145	CcSEcCtD
Zoledronate—Oedema peripheral—Doxorubicin—muscle cancer	0.000229	0.00145	CcSEcCtD
Zoledronate—Dysgeusia—Methotrexate—muscle cancer	0.000229	0.00144	CcSEcCtD
Zoledronate—Asthenia—Etoposide—muscle cancer	0.000228	0.00144	CcSEcCtD
Zoledronate—Connective tissue disorder—Doxorubicin—muscle cancer	0.000228	0.00144	CcSEcCtD
Zoledronate—Urethral disorder—Doxorubicin—muscle cancer	0.000228	0.00144	CcSEcCtD
Zoledronate—Back pain—Methotrexate—muscle cancer	0.000226	0.00143	CcSEcCtD
Zoledronate—Pruritus—Etoposide—muscle cancer	0.000225	0.00142	CcSEcCtD
Zoledronate—Vision blurred—Methotrexate—muscle cancer	0.00022	0.00139	CcSEcCtD
Zoledronate—Diarrhoea—Etoposide—muscle cancer	0.000218	0.00137	CcSEcCtD
Zoledronate—Eye disorder—Doxorubicin—muscle cancer	0.000217	0.00137	CcSEcCtD
Zoledronate—Ill-defined disorder—Methotrexate—muscle cancer	0.000217	0.00137	CcSEcCtD
Zoledronate—Anaemia—Methotrexate—muscle cancer	0.000216	0.00136	CcSEcCtD
Zoledronate—Cardiac disorder—Doxorubicin—muscle cancer	0.000216	0.00136	CcSEcCtD
Zoledronate—Flushing—Doxorubicin—muscle cancer	0.000216	0.00136	CcSEcCtD
Zoledronate—Angiopathy—Doxorubicin—muscle cancer	0.000211	0.00133	CcSEcCtD
Zoledronate—Malaise—Methotrexate—muscle cancer	0.000211	0.00133	CcSEcCtD
Zoledronate—Dizziness—Etoposide—muscle cancer	0.00021	0.00133	CcSEcCtD
Zoledronate—Immune system disorder—Doxorubicin—muscle cancer	0.00021	0.00132	CcSEcCtD
Zoledronate—Vertigo—Methotrexate—muscle cancer	0.00021	0.00132	CcSEcCtD
Zoledronate—Mediastinal disorder—Doxorubicin—muscle cancer	0.000209	0.00132	CcSEcCtD
Zoledronate—Leukopenia—Methotrexate—muscle cancer	0.000209	0.00132	CcSEcCtD
Zoledronate—Chills—Doxorubicin—muscle cancer	0.000208	0.00132	CcSEcCtD
Zoledronate—Arrhythmia—Doxorubicin—muscle cancer	0.000208	0.00131	CcSEcCtD
Zoledronate—Alopecia—Doxorubicin—muscle cancer	0.000205	0.0013	CcSEcCtD
Zoledronate—Cough—Methotrexate—muscle cancer	0.000204	0.00129	CcSEcCtD
Zoledronate—Mental disorder—Doxorubicin—muscle cancer	0.000204	0.00129	CcSEcCtD
Zoledronate—Convulsion—Methotrexate—muscle cancer	0.000202	0.00128	CcSEcCtD
Zoledronate—Vomiting—Etoposide—muscle cancer	0.000202	0.00128	CcSEcCtD
Zoledronate—Erythema—Doxorubicin—muscle cancer	0.000202	0.00128	CcSEcCtD
Zoledronate—Malnutrition—Doxorubicin—muscle cancer	0.000202	0.00128	CcSEcCtD
Zoledronate—Rash—Etoposide—muscle cancer	0.000201	0.00127	CcSEcCtD
Zoledronate—Dermatitis—Etoposide—muscle cancer	0.0002	0.00127	CcSEcCtD
Zoledronate—Headache—Etoposide—muscle cancer	0.000199	0.00126	CcSEcCtD
Zoledronate—Arthralgia—Methotrexate—muscle cancer	0.000199	0.00126	CcSEcCtD
Zoledronate—Chest pain—Methotrexate—muscle cancer	0.000199	0.00126	CcSEcCtD
Zoledronate—Myalgia—Methotrexate—muscle cancer	0.000199	0.00126	CcSEcCtD
Zoledronate—Dysgeusia—Doxorubicin—muscle cancer	0.000198	0.00125	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000197	0.00125	CcSEcCtD
Zoledronate—Discomfort—Methotrexate—muscle cancer	0.000196	0.00124	CcSEcCtD
Zoledronate—Back pain—Doxorubicin—muscle cancer	0.000196	0.00124	CcSEcCtD
Zoledronate—Muscle spasms—Doxorubicin—muscle cancer	0.000194	0.00123	CcSEcCtD
Zoledronate—Confusional state—Methotrexate—muscle cancer	0.000192	0.00121	CcSEcCtD
Zoledronate—Anaphylactic shock—Methotrexate—muscle cancer	0.000191	0.0012	CcSEcCtD
Zoledronate—Vision blurred—Doxorubicin—muscle cancer	0.000191	0.0012	CcSEcCtD
Zoledronate—Infection—Methotrexate—muscle cancer	0.000189	0.0012	CcSEcCtD
Zoledronate—Nausea—Etoposide—muscle cancer	0.000189	0.00119	CcSEcCtD
Zoledronate—Ill-defined disorder—Doxorubicin—muscle cancer	0.000188	0.00118	CcSEcCtD
Zoledronate—Nervous system disorder—Methotrexate—muscle cancer	0.000187	0.00118	CcSEcCtD
Zoledronate—Anaemia—Doxorubicin—muscle cancer	0.000187	0.00118	CcSEcCtD
Zoledronate—Thrombocytopenia—Methotrexate—muscle cancer	0.000187	0.00118	CcSEcCtD
Zoledronate—Agitation—Doxorubicin—muscle cancer	0.000186	0.00117	CcSEcCtD
Zoledronate—Skin disorder—Methotrexate—muscle cancer	0.000185	0.00117	CcSEcCtD
Zoledronate—Hyperhidrosis—Methotrexate—muscle cancer	0.000184	0.00116	CcSEcCtD
Zoledronate—Malaise—Doxorubicin—muscle cancer	0.000182	0.00115	CcSEcCtD
Zoledronate—Vertigo—Doxorubicin—muscle cancer	0.000182	0.00115	CcSEcCtD
Zoledronate—Anorexia—Methotrexate—muscle cancer	0.000182	0.00115	CcSEcCtD
Zoledronate—Syncope—Doxorubicin—muscle cancer	0.000181	0.00115	CcSEcCtD
Zoledronate—Leukopenia—Doxorubicin—muscle cancer	0.000181	0.00114	CcSEcCtD
Zoledronate—Palpitations—Doxorubicin—muscle cancer	0.000179	0.00113	CcSEcCtD
Zoledronate—Hypotension—Methotrexate—muscle cancer	0.000178	0.00112	CcSEcCtD
Zoledronate—Loss of consciousness—Doxorubicin—muscle cancer	0.000178	0.00112	CcSEcCtD
Zoledronate—Cough—Doxorubicin—muscle cancer	0.000176	0.00111	CcSEcCtD
Zoledronate—Convulsion—Doxorubicin—muscle cancer	0.000175	0.00111	CcSEcCtD
Zoledronate—Hypertension—Doxorubicin—muscle cancer	0.000175	0.0011	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000174	0.0011	CcSEcCtD
Zoledronate—Insomnia—Methotrexate—muscle cancer	0.000172	0.00109	CcSEcCtD
Zoledronate—Arthralgia—Doxorubicin—muscle cancer	0.000172	0.00109	CcSEcCtD
Zoledronate—Chest pain—Doxorubicin—muscle cancer	0.000172	0.00109	CcSEcCtD
Zoledronate—Myalgia—Doxorubicin—muscle cancer	0.000172	0.00109	CcSEcCtD
Zoledronate—Anxiety—Doxorubicin—muscle cancer	0.000172	0.00108	CcSEcCtD
Zoledronate—Paraesthesia—Methotrexate—muscle cancer	0.000171	0.00108	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000171	0.00108	CcSEcCtD
Zoledronate—Discomfort—Doxorubicin—muscle cancer	0.00017	0.00107	CcSEcCtD
Zoledronate—Dyspnoea—Methotrexate—muscle cancer	0.00017	0.00107	CcSEcCtD
Zoledronate—Somnolence—Methotrexate—muscle cancer	0.000169	0.00107	CcSEcCtD
Zoledronate—Dry mouth—Doxorubicin—muscle cancer	0.000168	0.00106	CcSEcCtD
Zoledronate—Dyspepsia—Methotrexate—muscle cancer	0.000168	0.00106	CcSEcCtD
Zoledronate—Confusional state—Doxorubicin—muscle cancer	0.000166	0.00105	CcSEcCtD
Zoledronate—Decreased appetite—Methotrexate—muscle cancer	0.000166	0.00105	CcSEcCtD
Zoledronate—Oedema—Doxorubicin—muscle cancer	0.000165	0.00104	CcSEcCtD
Zoledronate—Anaphylactic shock—Doxorubicin—muscle cancer	0.000165	0.00104	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000165	0.00104	CcSEcCtD
Zoledronate—Fatigue—Methotrexate—muscle cancer	0.000164	0.00104	CcSEcCtD
Zoledronate—Infection—Doxorubicin—muscle cancer	0.000164	0.00104	CcSEcCtD
Zoledronate—Pain—Methotrexate—muscle cancer	0.000163	0.00103	CcSEcCtD
Zoledronate—Shock—Doxorubicin—muscle cancer	0.000162	0.00103	CcSEcCtD
Zoledronate—Nervous system disorder—Doxorubicin—muscle cancer	0.000162	0.00102	CcSEcCtD
Zoledronate—Thrombocytopenia—Doxorubicin—muscle cancer	0.000162	0.00102	CcSEcCtD
Zoledronate—Tachycardia—Doxorubicin—muscle cancer	0.000161	0.00102	CcSEcCtD
Zoledronate—Skin disorder—Doxorubicin—muscle cancer	0.00016	0.00101	CcSEcCtD
Zoledronate—Hyperhidrosis—Doxorubicin—muscle cancer	0.00016	0.00101	CcSEcCtD
Zoledronate—Anorexia—Doxorubicin—muscle cancer	0.000157	0.000993	CcSEcCtD
Zoledronate—Feeling abnormal—Methotrexate—muscle cancer	0.000157	0.000992	CcSEcCtD
Zoledronate—Gastrointestinal pain—Methotrexate—muscle cancer	0.000156	0.000984	CcSEcCtD
Zoledronate—Hypotension—Doxorubicin—muscle cancer	0.000154	0.000974	CcSEcCtD
Zoledronate—Urticaria—Methotrexate—muscle cancer	0.000151	0.000956	CcSEcCtD
Zoledronate—Abdominal pain—Methotrexate—muscle cancer	0.000151	0.000951	CcSEcCtD
Zoledronate—Body temperature increased—Methotrexate—muscle cancer	0.000151	0.000951	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00015	0.00095	CcSEcCtD
Zoledronate—Insomnia—Doxorubicin—muscle cancer	0.000149	0.000943	CcSEcCtD
Zoledronate—Paraesthesia—Doxorubicin—muscle cancer	0.000148	0.000936	CcSEcCtD
Zoledronate—Dyspnoea—Doxorubicin—muscle cancer	0.000147	0.000929	CcSEcCtD
Zoledronate—Somnolence—Doxorubicin—muscle cancer	0.000147	0.000927	CcSEcCtD
Zoledronate—Dyspepsia—Doxorubicin—muscle cancer	0.000145	0.000917	CcSEcCtD
Zoledronate—Decreased appetite—Doxorubicin—muscle cancer	0.000143	0.000906	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000142	0.0009	CcSEcCtD
Zoledronate—Fatigue—Doxorubicin—muscle cancer	0.000142	0.000899	CcSEcCtD
Zoledronate—Pain—Doxorubicin—muscle cancer	0.000141	0.000891	CcSEcCtD
Zoledronate—Constipation—Doxorubicin—muscle cancer	0.000141	0.000891	CcSEcCtD
Zoledronate—Hypersensitivity—Methotrexate—muscle cancer	0.00014	0.000887	CcSEcCtD
Zoledronate—Asthenia—Methotrexate—muscle cancer	0.000137	0.000864	CcSEcCtD
Zoledronate—Feeling abnormal—Doxorubicin—muscle cancer	0.000136	0.000859	CcSEcCtD
Zoledronate—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000135	0.000852	CcSEcCtD
Zoledronate—Pruritus—Methotrexate—muscle cancer	0.000135	0.000852	CcSEcCtD
Zoledronate—Urticaria—Doxorubicin—muscle cancer	0.000131	0.000828	CcSEcCtD
Zoledronate—Body temperature increased—Doxorubicin—muscle cancer	0.00013	0.000824	CcSEcCtD
Zoledronate—Abdominal pain—Doxorubicin—muscle cancer	0.00013	0.000824	CcSEcCtD
Zoledronate—Diarrhoea—Methotrexate—muscle cancer	0.00013	0.000824	CcSEcCtD
Zoledronate—Dizziness—Methotrexate—muscle cancer	0.000126	0.000796	CcSEcCtD
Zoledronate—Hypersensitivity—Doxorubicin—muscle cancer	0.000122	0.000768	CcSEcCtD
Zoledronate—Vomiting—Methotrexate—muscle cancer	0.000121	0.000765	CcSEcCtD
Zoledronate—Rash—Methotrexate—muscle cancer	0.00012	0.000759	CcSEcCtD
Zoledronate—Dermatitis—Methotrexate—muscle cancer	0.00012	0.000758	CcSEcCtD
Zoledronate—Headache—Methotrexate—muscle cancer	0.000119	0.000754	CcSEcCtD
Zoledronate—Asthenia—Doxorubicin—muscle cancer	0.000118	0.000748	CcSEcCtD
Zoledronate—Pruritus—Doxorubicin—muscle cancer	0.000117	0.000737	CcSEcCtD
Zoledronate—Nausea—Methotrexate—muscle cancer	0.000113	0.000715	CcSEcCtD
Zoledronate—Diarrhoea—Doxorubicin—muscle cancer	0.000113	0.000713	CcSEcCtD
Zoledronate—Dizziness—Doxorubicin—muscle cancer	0.000109	0.000689	CcSEcCtD
Zoledronate—Vomiting—Doxorubicin—muscle cancer	0.000105	0.000663	CcSEcCtD
Zoledronate—Rash—Doxorubicin—muscle cancer	0.000104	0.000657	CcSEcCtD
Zoledronate—Dermatitis—Doxorubicin—muscle cancer	0.000104	0.000657	CcSEcCtD
Zoledronate—Headache—Doxorubicin—muscle cancer	0.000103	0.000653	CcSEcCtD
Zoledronate—Nausea—Doxorubicin—muscle cancer	9.8e-05	0.000619	CcSEcCtD
